questionable metaplastic process has been suggested to explain the apparent transformation of these ovarian surface cells to serous, endometrioid, mucinous, clear cell, and other epithelial neoplasm.
In recent years, entirely new concepts concerning the origin and pathogenesis of ovarian epithelial tumors have been advanced and were recently summarized by Kurman and Shih [ 4 ] .
According to this hypothesis, most ovarian epithelial neoplasms are considered to be of extraovarian origin. Thus, it has been suggested that serous carcinomas develop from the fimbriated portion of the fallopian tube, endometrioid, and clear cell tumors from endometrial tissue passing through the fallopian tube resulting in endometriosis and mucinous as well as Brenner tumors arise from transitional-type epithelial nests at the tubal-mesothelial junction by a process of metaplasia.
Admittedly, much of the above still remains to be proven, but these preliminary data are of great interest and may find support in recent molecular and gene expression studies.
Serous Tumors
The vast majority of high-grade ovarian carcinomas are of the serous type. It is now being recognized that these tumors are morphologically very heterogenous which constitutes most likely an expression of their genetic heterogeneity [ 3 ] . Most serous carcinomas not only demonstrate papillary features, but also glandular, cribriform and solid architecture. Squamous metaplasia has also been described in these neoplasms. Thus, it may be difficult in some of these cases to differentiate serous from other ovarian epithelial tumors, such as endometrioid, mucinous, or clear cell carcinoma, when adhering only to the WHO classification and to the traditional morphologic criteria of ovarian tumors [ 3 ] .
Most useful in the differential diagnosis between ovarian high-grade serous carcinoma and other epithelial neoplasms especially endometrioid carcinoma is widespread WT 1 (Wilms tumor protein, a suppressor gene) expression [ 6 ] as well as p53 (tumor suppressor gene) overexpression and mutation which are characteristic for serous high-grade tumors and are absent in most other ovarian carcinomas ( Fig. 10 .1 ) [ 3, 7 ] . Furthermore, precursor lesions, such as the coexistence of a serous ovarian borderline tumor with an epithelial malignant neoplasm favors the diagnosis of ovarian low-grade serous carcinoma in the latter [ 8 ] while tubal intraepithelial carcinoma is characteristically associated with high-grade serous tumor ( Fig. 10 .2 ) [ 9 ] .
Mucinous Tumors
Less than 3% of ovarian mucinous carcinomas of the intestinal type are primary tumors. The vast majority are metastatic from the intestinal tract [ 10 ] . Most ovarian mucinous tumors are of the intestinal type. The so-called müllerian or seromucinous (endocervical) type ovarian tumors are uncommon. They are sometimes included in the group of mixed epithelial ovarian tumors [ 3 ] .
Since many mucinous tumors lack apical mucin, they may be erroneously diagnosed as other ovarian epithelial neoplasms, especially as endometrioid carcinoma.
Immunohistochemical staining of these tumors is crucial in reaching a correct diagnosis, since primary mucinous tumors show predominantly cytokeratin 7 with lesser expression of cytokeratin 20. Most importantly, CDX2 is negative or occasionally only focally positive in primary mucinous ovarian tumors, while in metastatic carcinomas from the intestinal tract, CDX2 and cytokeratin 20 are strongly and diffusely positive while cytokeratin 7 is absent or only focally positive ( Fig. 10.3 ) [ 11 ] . The precursor lesion of ovarian mucinous carcinoma is the mucinous borderline tumor ( Fig. 10.4 ).
Endometrioid Tumors
According to Czernobilsky et al. [ 12 ] , ovarian endometrioid carcinoma constituted about 23% of all ovarian primary carcinomas in 1970.
With the emergence of immunohistochemical markers, the recognition of precursor lesions and the change in our approach to classic morphologic features endometrioid carcinoma nowadays represents only about 10% of all ovarian carcinomas [ 13 ] . Many of erroneously diagnosed endometrioid carcinomas are indeed serous tumors. Thus, endometrioid carcinomas are commonly associated with endometriosis, endometrioid adenofibroma, endometrioid borderline tumors as well as synchronous endometrioid intrauterine carcinoma [ 2, 3, 14 ] . These precursor lesions are absent in serous carcinomas ( Fig. 10 .5 ). Finally, endometrioid carcinomas in contrast to serous carcinomas, lack WT 1 [ 15 ] and p53 overexpression, and usually express estrogen and progesterone receptors [ 3 ] .
Clear Cell Tumors
This tumor shows a papillary, tubulocystic, and solid architecture with typical hobnail type and clear cells. An oxyphilic cell type has also been described. A typical feature of these tumors is the large, highly atypical nuclei with large nucleoli.
Positive stainings for estrogen and progesterone receptors as well as WT 1 expression exclude a diagnosis of clear cell carcinoma [ 16 ] . P53 may be evident but not in the diffuse, prominent way as it is seen in serous tumors [ 17 ] . Hepatocyte nuclear factor (HNF) 1 b (1beta) has been recently described as a reliable immunomarker in ovarian clear cell tumors [ 18, 19 ] . Ovarian carcinomas composed of clear cell elements mixed with other cell types, such as endometrioid or serous carcinoma should not be diagnosed as clear cell carcinoma but rather as serous carcinoma [ 20 ] . In other words, the diagnosis of clear cell carcinoma should be reserved for tumors with a homogenous clear cell population and highly atypical nuclei [ 21 ] .
Precursor lesions of clear cell carcinoma include endometriosis and clear cell adenofibromas 
Transitional Cell Tumors
Most of the tumors classified as transitional cell carcinoma in the WHO classification [ 1 ] are actually high-grade serous or high-grade endometrioid carcinomas and frequently express p53 and WT 1 , which are typical of serous carcinomas ( Fig. 10.7 ) [ 22 ] . The only exception appears to be the benign Brenner tumor which is positive for uroplakin and may thus be of urothelial derivation ( Fig. 10.8 ) [ 23 ] . 
Mixed Epithelial Ovarian Tumors
These are tumors showing two or more distinctive types of neoplasms constituting at least 10% of the tumor. According to Soslow [ 3 ] , the tumor elements in mixed epithelial tumors should be separable and as such diagnosable as separate neoplasms. Notwithstanding the above definition of mixed epithelial tumors, most of these are considered to be high-grade serous carcinomas, which are supported by diffuse WT 1 staining [ 3 ] .
Undifferentiated Carcinomas
Most of these tumors which are not histologically classifiable should also be diagnosed as highgrade serous carcinomas especially if the tumor is WT 1 positive [ 3 ] and other possibilities, such as metastases to the ovary are excluded ( Fig. 10.9 ). Tables 10.1 -10.3 summarize some of the above discussed data. antonio.russo@usa.net
Summary
The emergence of new data in recent years concerning the origin and pathogenesis of epithelial ovarian carcinomas culminating in a theory that the latter are of extraovarian origin, the morphologic variability of hitherto well-defined ovarian tumors, the presence of precursor lesions, relatively specific immunohistochemical markers as well as molecular and genetic features, require a reassessment of various aspects of ovarian epithelial tumors. In addition, it has been proposed by Kurman et al. [ 2, 4, 24 ] that ovarian epithelial tumors be divided in type I and type II tumors, similar to the already existing division of endometrial uterine carcinoma.
According to this proposal, type I tumors which are relatively genetically stable consist of micropapillary serous, mucinous, and endometrioid carcinomas. Type II tumors are genetically highly unstable aggressive neoplasms, such as high-grade serous carcinomas, carcinosarcomas, and undifferentiated carcinoma.
The two groups vary in their histologic appearance, precursor lesions, and immunophenotype as well as by molecular and genetic features. The clinical course and prognosis also differ in these two groups. Since clear cell carcinomas show clinical morphological, immunohistochemical, and genetic features which are shared to some degree by both type I and type II ovarian tumors, they cannot at this time be definitely classified [ 2 ] .
Finally, it is to be expected that a different therapeutic approach to patients with group I and II tumors, including screening and prevention may result in a more favorable response and improve prognosis especially in the patients with high-grade ovarian cancer.
Molecular Features and Gene Expression Studies
Despite the poor prognosis and the importance of early diagnosis, there are no reliable methods for detection of ovarian cancer in the early stages of disease. Since patients diagnosed with stage I epithelial ovarian cancers (EOCs) have a 90% survival rate, it is important to identify novel ovarian cancer biomarkers with potential utility in early stage screening. Little is known of the molecular genetic changes that are associated with the development of invasive ovarian cancer. Cytogenetic analyses of epithelial ovarian tumors have shown frequent structural aberrations of chromosomes 1, 3, 6, and 11, suggesting that inactivation of genes located on these chromosomes may be important in ovarian tumorigenesis. A high frequency of allelic losses (LOH) was observed on 11p, 13q, and 17p. The loss of tumor-suppressor genes on 13q and 17p may be involved in early events of ovarian tumorigenesis and changes on 11p in later events [ 25 ] .
With regard to the application of new genomic technologies, the gene expression analysis has allowed to identify important differentially expressed genes and molecular pathways that may help to understand the evolution from normal ovarian tissue to ovarian cancer [ 26 ] . Several studies have shown distinctive gene expression patterns that can differentiate between histological subtypes of ovarian carcinoma [27] [28] [29] [30] [31] or predict response to chemotherapy or survival [32] [33] [34] [35] . The different histological subclasses and the clinical phenotypes displayed by EOCs are hypothesized to be driven by specific genes. Differentially expressed genes are included in pathways involved in chromosomal instability, invasion cell, motility, proliferation, and gene silencing and provided new insights into the origin of this cancer [ 36 ] . In addition, differences in gene expression patterns may help to characterize ovarian cancer and to identify potential targets for effective prevention and treatment of disease. Normal epithelial ovarian samples have been compared with tumor samples in gene expression profiling studies, generating very distinct groups in hierarchical clustering.
The choice of a normal control that can be compared to EOC samples in microarray analyses can strongly influence the identification of differentially expressed genes. Seventy-five gene expression profiles of EOC subhistotypes were compared by Zorn et al. to determine the similarities and differences between all samples. The gene signature generated from Zorn et al. identified 166 genes that distinguished the samples into three subtypes: endometrioid, serous, and clear cell [ 37 ] . Instead, Schwartz et al. found 158 differentially expressed genes histotype-specific for the endometrioid, serous, clear cell, and mucinous ovarian cancers. Of these 158 genes, 73 genes were clear cell histotype-specific, 64 genes were mucinous histotype-specific, 19 genes were specific for serous, and 2 genes were specific for endometrioid. These data showed that there are large expression differences between the various histological types of ovarian cancer [ 38 ] . There is a small set of upregulated genes related to ovarian clear cell tumors including SOD2 (superoxide dismutase), GPX3 (glutathione peroxidase 3), RBP4 (retinol binding protein 4), UGT1A1 (UDP glycosyltrans-ferase1family, polypeptideA1), TFPI2 (tissue factor pathway inhibitor), FXYD2 (FXYD domain containing ion transport regulator 2), GLRX (Glutaredoxin), and ANXA4 (Annexin). These genes overlap with genes identified by Zorn et al. [ 29 ] . Two of these genes are associated with chemotherapy response: UGT1A1 detoxifies the active metabolite of irinotecan, whereas ANXA4 has been associated with paclitaxel resistance [ 39, 40 ] . SOD2 , GLRX , and GPX3 are involved in oxidative stress response and particularly high levels of these in clear cell histotypes may make these tumors more resistant to chemotherapy [ 38 ] (Table 10. 
).
A microarray analysis of 103 primary ovarian cancers has suggested the contributions of origin and histotype on the tumor gene expression profile [ 41 ] . Sixty-two differentially expressed genes were observed between endometrioid versus serous histotypes. Of these 62 genes, endometrioid carcinomas often showed highly expressed TFF3 (trefoil factor 3), SFN (stratifin), MSX1 (msh homeobox 1), and CEACAM1b (carcinoembryonic antigen-related cell adhesion molecule) genes. Serous carcinomas often showed high expression of the following genes: FOLR1 (folate receptor 1), PTGS1 (prostaglandin-endoperoxide synthase 1), WT1 (Wilms tumor 1), and GAS6 (growth arrest-specific 6). By an extensive Affymetrix microarray analysis, mucinous ovarian cancer was differentiated from the other subtypes of ovarian cancer, due to different gene expression profiles [ 38, 42, 43 ] . In mucinos ovarian tumors, Wamunyokoli et al. [ 42 ] identified specific differentially expressed genes involved in the following pathways: proliferation and cell cycle regulation ( ERBB3 , CCND1 , TGF -a), transformation ( K-ras2 , c-JUN , YES1 , ECT2 ), signal transduction ( CAV-1 and SPRY1 ), cytoskeleton rearrangement/signal transduction ( CDC42 , RAC1 , IQGAP2 , RALA , Cortactin), and drug resistance ( ABCC6 and ABCC3 ).
In conclusion, clear cell, serous, endometrioid, and mucinous histotypes appear to show specific gene expression signatures. These differences in gene expression profiles could be useful in the treatment of the different histotypes. Using a Serial Analysis of Gene Expression (SAGE), David G. Peters et al. [ 44 ] have identified several potentially novel biomarkers whose expression is elevated in ovarian cancer. These proteins include CD9, HMGA1, AHCY, GNAI2, CCT3, and TACC3.
Moreover, it has recently been demonstrated by some research groups that the gene expression signatures determined by microarray analysis may act as a prognostic factor in EOC [ 45 ] . Several markers with prognostic value have been identified by specific molecular studies. HER2/neu and EGFR overexpression has been related to poor prognosis [46] [47] [48] . Clinical studies have shown that TP53 overexpression is related with shorter survival in ovarian cancer [ 49 ] and resistance to platinum-based chemotherapy [ 50 ] . Other molecular studies by microarray identified several genes responsible for platinum resistance involved in the following pathways: proliferation ( FRA1 , ETV4 , IGFBP3 , STAT1 ), cell-cycle control ( CDKN1A , CDKN1C , CDC25C , PLK3 ), apoptosis ( BAK , BAX , STAT1 , c-JUN , TP53 ), DNA repair ( XRCC9 , PCNA , TP53 , DDB2 , GADD45B , POLH ), and energy regulation metabolism (STARD4 and FDXR) [ 51 ] . Nevertheless, the NAC-1 expression modulates taxol resistance in ovarian cancer and may provide an effective target for chemotherapeutic intervention in taxol-resistant tumors [ 52 ] . The loss of protein p27 is an important prognostic marker for predicting disease recurrence in primary ovarian cancer [ 53 ] . Moreover, the amplification of oncogene MYC and increased expression levels of cyclin E have been associated with poor prognosis [ 54, 55 ] . In a recent work [ 56 ] , the mammaglobin B ( MGB-2 ) gene expression was evaluated in ovarian cancer tissues and in normal ovarian controls by quantitative real-time PCR and then by immunohistochemistry. MGB-2 expression levels were found increased in EOC compared to normal ovarian controls, both at protein level and mRNA. MGB-2 expressing tumors were related to clinicopathologic features of the less aggressive tumors. This finding suggest that MGB-2 is an independent prognostic marker in EOC and its expression is correlated with reduced risk of disease recurrence [ 56 ] .
Moreover, for the first time, the epithelial cell adhesion molecule (Ep-CAM) overexpression was associated with a decreased overall survival. Ep-CAM represents a novel independent prognostic marker for reduced survival of patient with EOC [ 57 ] .
In conclusion, whole genome expression profiling has become a vital tool for identifying differentially expressed genes in EOCs, in order to potentially prolong the survival of women diagnosed with this disease [ 58 ] .
